Big Pharma-backed Seawolf surfaces with $100M to hand, $1.2B Sanofi DNA med pact

Sunset
“Our Big Pharma investors are ... all big believers in the promise of DNA-based medicines,” Seawolf CEO Elizabeth Alcamo told Fierce. (iStock / Getty Images Plus)

Gene therapy biotech Seawolf Therapeutics has emerged from the deep with $100 million to fuel its DNA therapeutic ambitions and a billion-dollar deal with Sanofi.

The $100 million comes from a combination of a seed round, which was led by Versant Ventures, and a series A that was backed by heavy hitters like Eli Lilly and the Novartis Venture Fund, as well as Versant, MPM BioImpact, CRISPR Therapeutics, Sixty Degree Capital, Alexandria Venture Investments and the National Bleeding Disorders Foundation’s philanthropic venture arm Pathway to Cures.

The Big Pharma backing didn't end with the fundraise. Seawolf used Monday's announcement to disclose a “multi-target research collaboration and exclusive license agreement” with Sanofi to develop undisclosed therapies for bleeding disorders and additional unnamed indications. That deal puts the biotech in line for up to $1.2 billion in milestone payments, as well as tiered royalties if any drugs make it to market.

Seawolf’s redosable DNA delivery platform, called Trident, combines a lipid nanoparticle, a proprietary DNA structure and an “auxiliary factor” protein within the same payload that makes the genetic delivery more accessible to the nucleus, CEO and founder Elizabeth Alcamo, Ph.D., explained to Fierce via email.

The San Diego-based company got its start in 2021 and has established a lead program targeting metabolic diseases. The goal is for patients who need regular infusions of biologics such as antibodies or recombinant proteins to potentially manage their disease with dosing as infrequently as every six months or every year, according to Alcamo.

“The system builds on the technological advances that gave us RNA-based lipid nanoparticles with innovations in three key areas to adapt them for DNA,” Alcamo said. “The new class of LNP-based medicines created by this combination offers a scalable solution for continuous protein therapy and gene supplementation and, unlike AAV, an opportunity to repeat dos[ing].”

“Our Big Pharma investors are—from what I can tell—all big believers in the promise of DNA-based medicines and recognize the Trident system’s potential to unlock the full promise of DNA medicines as treatment options for patients with serious diseases,” the CEO added.

The kinds of lipid nanoparticles that work for RNA don’t work well for DNA, Alcamo pointed out. The company has built a “barcoded high-throughput screen in nonhuman primates to identify a proprietary, targetable LNP formulation bespoke for delivering DNA and RNA,” pairing that with DNA structures that are less immunogenic than the plasmids that would typically be used as therapeutics.

This combination of lipid nanoparticle and DNA enables individualized patient titration, Alcamo said, “allowing each patient to be redosed until they reach the level of expression or gene correction required to address their specific needs.”